<p>Baloxavir marboxil is a novel, oral, antiviral agent approved by the Food and Drug Administration (FDA) on Oct. 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older.</p>

Baloxavir Marboxil (Xofluza)

April 1, 2019

Baloxavir marboxil is a novel, oral, antiviral agent approved by the Food and Drug Administration (FDA) on Oct. 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older.

Issue Date: April 1, 2019

Table of Contents

Financial Disclosure: Peer Reviewer Patrick Joseph, MD, is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Infectious Disease Alert’s Editor Stan Deresinski, MD, FACP, FIDSA, Updates Author Carol A. Kemper, MD, FACP, Peer Reviewer Kiran Gajurel, MD, Executive Editor Shelly Morrow Mark, Editor Jonathan Springston, and Editorial Group Manager Terrey L. Hatcher report no financial relationships to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements